Ipragliflozin
Drugoral tablet
Other names: ASP1941
NCT Number: NCT01071850
Evaluate the efficacy, safety, and tolerability of multiple doses of ASP1941 compared to placebo over 12 weeks of therapy in adult patients with type 2 diabetes mellitus.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
BIOMELAB, Barranquilla, Colombia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
systolic blood pressure >180 mmHg or a diastolic blood pressure of
>110mmHg
antigen, hepatitis C virus antibody or is known positive for HIV1 and/or
HIV2
months
treated basal or squamous cell carcinoma of the skin or of the cervix
oral tablet
Other names: ASP1941
oral tablet
oral tablet
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: 12 weeks
Astellas Pharma Inc
Industry
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Patients With Type 2 Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT04190251
Behavior, Chronic Disease
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT00339482
Cardiovascular Diseases, Diabetes Mellitus
Phoenix, Arizona, United States
View Trial DetailsNCT07663682
Diabetes Mellitus, Diabetes Mellitus, Type 2
Taiyuan, Shanxi, China
View Trial Details